Cookies
Please review our Privacy Policy. This website uses cookies. By using our website without changing your cookie settings you agree to our use of Cookies as described in our Privacy Policy.
Necessary cookies make a website usable by enabling basic functions such as page navigation and access to secure areas of the website. These cookies cannot be switched off in Parexel’s systems. They are usually only set in response to actions made by you, which amount to a request for services, such as setting your privacy preferences, logging in or completing forms. You may be able to decline these cookies through your browser, but necessary parts of the website will then not work. These cookies do not store any personally identifiable information.
Cookie | Expiry | Domain | Company | Purpose |
---|---|---|---|---|
Cookie pxlCookieConsent | Expiry Session | Domain staging.tannwestlake.com | Company Parexel | Purpose Necessary |
DescriptionStores your cookie consent session for our site. It contains no information other than whether you have opted in or out for each cookie level. | ||||
Cookie wordpress_test_cookie | Expiry Session | Domain staging.tannwestlake.com | Company Parexel | Purpose Necessary |
DescriptionTests that the browser accepts cookies. |
Interleukin-18 Engineered for Resistance to IL-18 Binding Protein (IL-18BP) and Half-life Extension to Enhance its Therapeutic Potential
Jean Chamoun, Clifford DiLea, Kristiana Dreaden, Pinar Gurel, Josh Heiber, Robert G. Newman, Su-Ping Pearson, Chunhua Wang, Yanchun Zhao, and Mark Whitmore
Poster presented at the
AACR Annual Meeting 2024, April 5-10, 2024, San Diego, CA
All copyrights remain those of the copyright holder. This page will not be available after May 9, 2024.